AstraZeneca and its global biologics research and development arm, MedImmune, have announced positive overall survival (OS) results of the Phase III PACIFIC trial evaluating Imfinzi (durvalumab) for the treatment of unresectable stage III NSCL
More From BioPortfolio on "Interim analysis shows clinical benefit of Imfinzi for unresectable non-small cell lung cancer"